Daiwa Securities Group Inc. Increases Position in Becton Dickinson and Co (NYSE:BDX)

Daiwa Securities Group Inc. boosted its holdings in Becton Dickinson and Co (NYSE:BDX) by 31.2% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 13,801 shares of the medical instruments supplier’s stock after buying an additional 3,280 shares during the period. Daiwa Securities Group Inc.’s holdings in Becton Dickinson and were worth $3,447,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its stake in Becton Dickinson and by 22,485.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 6,545,502 shares during the last quarter. Ronna Sue Cohen lifted its stake in Becton Dickinson and by 24,129.0% in the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after purchasing an additional 5,710,365 shares during the last quarter. Norges Bank bought a new stake in Becton Dickinson and in the fourth quarter worth about $515,703,000. Morgan Stanley lifted its stake in Becton Dickinson and by 133.0% in the third quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock worth $723,303,000 after purchasing an additional 1,581,829 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its stake in Becton Dickinson and by 27.7% in the fourth quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock worth $437,966,000 after purchasing an additional 421,825 shares during the last quarter. Institutional investors and hedge funds own 85.24% of the company’s stock.

Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday. Wells Fargo & Co decreased their price target on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research note on Monday, May 13th. Barclays raised shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target for the company in a research note on Monday, May 13th. BMO Capital Markets decreased their price target on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research note on Friday, May 10th. Finally, Morgan Stanley decreased their price target on shares of Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a research note on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $255.31.

BDX stock traded up $1.71 during trading on Wednesday, hitting $235.68. 1,223,285 shares of the company’s stock traded hands, compared to its average volume of 1,276,401. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The firm has a market cap of $61.60 billion, a price-to-earnings ratio of 21.41, a PEG ratio of 1.71 and a beta of 1.16.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business had revenue of $4.20 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same period in the previous year, the company earned $2.65 earnings per share. The business’s revenue for the quarter was down .6% on a year-over-year basis. Analysts anticipate that Becton Dickinson and Co will post 11.7 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.31%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

In other Becton Dickinson and news, EVP Betty D. Larson sold 1,700 shares of Becton Dickinson and stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total value of $382,449.00. Following the transaction, the executive vice president now directly owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction on Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the transaction, the chief executive officer now directly owns 227,250 shares in the company, valued at $56,903,400. The disclosure for this sale can be found here. Insiders sold 31,384 shares of company stock worth $7,901,023 over the last ninety days. Corporate insiders own 0.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Daiwa Securities Group Inc. Increases Position in Becton Dickinson and Co (NYSE:BDX)” was originally published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://sundanceherald.com/2019/05/22/becton-dickinson-and-co-bdx-shares-bought-by-daiwa-securities-group-inc.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: What are retained earnings?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply